Diabetes Connections | Type 1 Diabetes

This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely below the skin, news about heart health and type 1, the next generation of weight loss drug and a big week for
sports on the highest level with type 1. And it's diabetes awareness momth!
It's all coming up right after this.
(AD BREAK)
Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
Diabetes Awareness Month – I've got some news there, but there are SO many campaigns and releases this month. I've always said it's always diabetes awareness month around here and these awareness campaigns are for the engeral ppulario. So I'm sure you're inundated – I'll highlight what I think it noteworthy.
We're in Phoenix this week for our last in person event of the year. This is a Club 1921 event for the whole community. We will have more of these next year – but our Next in person event will be Tampa in March for MNO – that's open and we have a flash sale until the end of this month.
Okay.. our top story this week:
XX
Some people with diabetes may have to switch continuous glucose monitors starting January 1, 2027, because of insurance coverage changes involving CVS Caremark and Aetna. According to the Diabetes Patient Advocacy Coalition, some plans are moving to exclusive contracts that favor Abbott's FreeStyle Libre over Dexcom. Not everyone will be affected, and some patients may still be able to get their preferred CGM covered through medical rather than pharmacy benefits. DPAC is pushing back, arguing that insurance contracts shouldn't force people to change diabetes technology that's working for them. The organization is encouraging people to contact CVS Caremark and Aetna leadership through its online advocacy campaign.
https://diabetespatientadvocacycoalition.quorum.us/campaign/cgmcvs
XX
Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app.
Statement from Dexcom:
We understand the concerns surrounding our roll out of our Terms of Use and Privacy Notice and recognize the importance of providing users with clear information.
 
 
These updates are intended to support the continued operation, security and innovation of our products, while providing greater transparency into how data may be collected and used. We take our responsibility to protect users' personal information seriously and remain committed to handling their data responsibly.
 
 
Like many digital services, continued use of the Dexcom app requires acceptance of the updated Terms of Use. Moving forward, users will have 30 days from acceptance to opt out of the arbitration provisions and may also opt out of certain cookies and data-sharing activities at any time.
 
 
We understand the importance of uninterrupted access to glucose data for people managing diabetes. We are reviewing how we communicate and implement changes like these in the future to ensure users have the information they need and a clear understanding of their choices.

 
XX
Senseonics announced the initiation of its first-in-human clinical study evaluating Freedom, an investigational next-generation CGM system designed to communicate directly with a mobile device without the need for an external on-body transmitter.
Unlike the current Eversense, which uses a removable transmitter worn over the implanted sensor, Freedom is designed to communicate directly with a smartphone using Bluetooth. The initial study will focus on safety, design, and wireless communication. Senseonics hopes to begin a larger clinical trial in 2027, with a possible commercial launch in 2028 if development and regulatory review go as planned.
Source: Drug Delivery Business News
XX
In patients with type 1 diabetes (T1D), having a laboratory A1c higher than the glucose management indicator (GMI), your CGM, was associated with more microvascular complications.
 Researchers in Spain studied more than 1,300 adults with type 1 diabetes and found that people whose laboratory A1C was significantly higher than their CGM estimate were more likely to have complications involving their eyes, kidneys, or nerves. Those with the largest discrepancies had nearly twice the odds of these complications, even after researchers accounted for other clinical and CGM measurements. The study doesn't establish that the mismatch causes complications, but researchers say looking at both numbers together may help doctors better assess individual risk.
Source: Medscape
XX
New research suggests that widely used tools for predicting heart disease risk may significantly underestimate that risk in people with type 1 diabetes. Researchers analyzed decades of data from more than 1,300 participants in the long-running DCCT/EDIC study and found that actual cardiovascular events occurred more frequently than several standard risk calculators predicted. Adding a coronary artery calcium scan, which looks for calcium buildup in the arteries, improved predictions somewhat, but not dramatically. The findings, presented at the 2026 European Association for the Study of Diabetes meeting, highlight the need for better heart disease risk assessment tools designed specifically for people with type 1.
Source: Medscape
XX
Eli Lilly is reporting impressive results for retatrutide, its experimental drug that targets three different hormone receptors, including GLP-1. In a Phase 3 study involving nearly 1,300 adults with type 2 diabetes, retatrutide lowered A1C by 2.2 percentage points, compared with 1.8 points for Ozempic. Participants taking retatrutide also lost an average of 44 to 47 pounds, roughly twice as much as those taking Ozempic. Side effects, including diarrhea and unusual skin sensations, were more common with retatrutide. The drug is not yet approved, and Lilly plans to seek FDA approval in early 2027.
Source: BioSpace
XX
It's official: MiniMed is now a fully independent company, completing its separation from longtime parent company Medtronic. MiniMed went public earlier this year, and Medtronic has now exchanged its remaining shares, ending its ownership stake in the diabetes technology business. MiniMed CEO Que Dallara says the independence gives the company more freedom to make decisions and advance diabetes care. The company is still working to separate some of its technology services from Medtronic, a process expected to continue into 2027.
Source: MedTech Dive
XX
Still to come, an implant designed to remove excess glucose without medication, help for younger adults with type 2, and type 1 hits the streets of new York.. right after this.
XX
Scientists in Switzerland and France have developed an experimental implant that removes excess glucose from the blood without using insulin or other diabetes medications. The tiny wireless device works with a continuous glucose monitor and uses an electrical reaction to convert glucose into a substance called gluconate, which is then cleared by the kidneys. In mice with type 2 diabetes and obesity, the device lowered blood sugar and reduced body weight by about 10% over six weeks. Researchers say the technology could eventually offer a new approach to treating type 2 diabetes, but it's still in the very early stages, with no human trials yet.
Source: Live Science
XX
A new study suggests that an intensive diet and exercise program can help some younger adults with type 2 diabetes achieve remission in just six months. Researchers followed 96 adults under age 45 and found that 54% of those in a medically supervised program achieved remission, compared with just 4% receiving standard care. The program included a very low-calorie diet of 800 to 900 calories per day during its initial phase, along with structured aerobic and strength training. Remission means blood sugar returns below the diabetes threshold without glucose-lowering medication, but it doesn't necessarily mean a permanent cure. These findings apply to type 2 diabetes, not type 1, and the intensive program was conducted under medical supervision.
Source: ScienceDaily
XX
Two big shoutouts for type 1 diabetes and sports. Major congrats to everyone who completed or even attempted the NYC Marathon – I'm in awe of how much training you've all put in. What an amazing accomplishment. And of course, I know some time has gone by, but one more mention of Garrett Mitchell from the World Series champion Milwakee Brewers.
 
A big week for people with type 1 diabetes in sports! Congratulations to everyone with T1D who took on the New York City Marathon, and a special shoutout to Milwaukee Brewers outfielder Garrett Mitchell. We'll have more on Mitchell and his story coming up.
XX
I anticipate a lot of diabetes month news and campaigns and I'll share on social if I find them interesting and actionable. I don't really do much that's different – every month is diabetes awareness month around here. I do think it's a wonderful time to get information out to the non-diabetes community. Project Blue Novmeber always does a great job all month long if you're looking to shrae iformatoin via social.
That's it for in the news!
This week on Diabetes Connections In the News… big insurance changes could affect your CGM coverage, a new study looks at why the difference between estimated A1C from CGM and the A1C from the lab could really matter to your health, Eversense CGM starts testing a new version that's completely below the skin, news about heart health and type 1, the next generation of weight loss drug and a big week for sports on the highest level with type 1. Plus, it's diabetes awareness month!
Our Community Commercial is for The Accessible Insulin Pump Task Force
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com 
Episode transcript:

What happened at the very first Breakthrough T1D Clinical and Research Congress? More than a thousand people from 33 countries came together to talk about everything from islet cell transplants and new treatments to screening, prevention, and the growing role of GLP-1 medications in type 1 diabetes.
I'm talking to Anastasia Albanese-O'Neill, vice president, medical affairs for Breakthrough, who joins us fresh off the conference to share the biggest headlines, what she's most excited about, and why she says we're at an inflection point in type 1 diabetes care.
We also talk about how even the most promising breakthrough won't make a difference unless people can actually access it.
This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.
More about the Congress here
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com

On this bonus episode of diabetes connections.. the creator of Gluki, a new app designed to help kids understand diabetes through games, rewards, and interactive learning.
I'm talking to Staci DePatie who lives with type 1.  Staci's working with students at UC Irvine to bring Gluki to life, including some interesting new AI features. We'll talk about how it all works, why she believes building what she calls "diabetes IQ" is so important, and I'll ask some questions about AI safety, cost, and whether kids really want to spend more time thinking about diabetes, even if it's as part of a game.
This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com

This week on Diabetes Connections In the News… a change from Dexcom sparks a big community response  New developments in the race to protect insulin-producing beta cells, Lilly's GLP-1 pill moves closer to approval in Europe, and could remote monitoring help kids with type 1 improve their glucose management? Plus, are pregnant women being left behind by automated insulin delivery technology? And a Major League moment to remember as a player with type 1 diabetes sends the Milwaukee Brewers to the World Series!
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com 
Transcript:
Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.
Who else is getting ready for 2027? I know, I can't believe it either but I'm already booking to speak and we've got events on the books. I will not wish the rest of this year away, we've still got a lot going on, but please follow along, I'll keep you posted on where we're going and what's up.
Off to Seattle in a couple of days for MNO..
Okay.. our top story this week:
XX
Dexcom is facing criticism from the diabetes community after users were presented with updated terms and conditions as they used the app.
The notification included the message, "Please uninstall app if you don't agree." Some users reported they couldn't get past the notification to view their glucose readings without accepting the terms.
The controversy centers on provisions involving mandatory arbitration and class action waivers. Those provisions can limit a user's ability to pursue certain legal claims against Dexcom in court, instead requiring disputes to be handled through individual arbitration. The updated terms also raise questions about data privacy and the use of information for artificial intelligence features.
Rob howe from Diabetics Doing Things has an itnerivew going live later this week with Peter Simpson, CTO of Dexcom. Rob released a short clip from that interview, and gave me permission to re-air part of it here..
(clip)
I have not yet confirmed with Dexcom, but others on social media say that Dexcom has since clarified that users can opt out of the arbitration provision and continue using the app. According to the terms shared by users, they have 30 days after accepting to opt out by emailing Dexcom's legal department with their name, address, and a statement declining arbitration.
I've reached out to Dexcom, but have not yet received a response, they say they are working on it. If we get it after this episode goes live, I'll jump on social with an update.
XX
Immunocore has announced that the first person with type 1 diabetes has received an experimental treatment in a Phase 1 clinical trial. The therapy, called IMC-S118AI, is designed to protect insulin-producing beta cells by targeting and switching off the immune cells that attack them in people with T1D. Unlike treatments that affect the entire immune system, this approach is designed to work specifically around the beta cells, with the goal of preserving the body's ability to produce insulin. Earlier laboratory research using human pancreatic tissue showed promising results, including reduced immune attacks on beta cells and preserved insulin secretion. The Phase 1 trial will now evaluate the treatment's safety, how it moves through the body, and whether it shows signs of working in people with T1D who have a specific genetic marker.
 
XX
SAB Biotherapeutics has received FDA Fast Track designation for SAB-142, an experimental immune therapy designed to slow the progression of type 1 diabetes in people who have recently been diagnosed. The treatment uses human antibodies produced through genetically engineered cattle, with the goal of protecting the body's insulin-producing cells from immune system attacks. SAB-142 is currently being studied in a Phase 2b clinical trial involving people within 100 days of a Stage 3 type 1 diabetes diagnosis, with results expected in the second half of 2027. A separate Phase 3 study is also evaluating the treatment in people diagnosed between 100 days and two years earlier. Fast Track designation could help speed the development and FDA review process, but it does not mean the treatment has been approved or proven effective.
https://www.globenewswire.com/news-release/2026/10/13/3379679/0/en/sab-bio-receives-fda-fast-track-designation-for-sab-142-in-stage-3-type-1-diabetes.html
XX
Eli Lilly's once-daily GLP-1 pill, Foundayo, has taken another step toward approval in Europe. A European Medicines Agency committee has recommended the drug for both weight management and treatment of type 2 diabetes in adults, with a final decision expected from the European Commission in the coming weeks. Foundayo, also known as orforglipron, works similarly to injectable GLP-1 medications but comes in pill form and can be taken at any time of day without restrictions on food or water. The drug was approved in the U.S. for weight management in April 2026, while FDA review for type 2 diabetes is still pending. If approved in Europe, Foundayo would compete with Novo Nordisk's oral GLP-1 medications, including the Wegovy pill for weight management and Rybelsus for type 2 diabetes.
https://www.pharmexec.com/view/ema-panel-backs-lilly-foundayo-obesity-type-2-diabetes-europe
XX
A small pilot program at UC Davis Health found that remotely monitoring glucose data between doctor visits helped young people with type 1 diabetes improve their blood sugar management. The four-month study included 20 children and teens with A1Cs above 8% who were already using continuous glucose monitors. Clinicians reviewed their CGM data weekly and reached out by phone, text, or online messaging when patients needed additional support. By the end of the program, average time-in-range increased from 34% to 40%, while time spent above target dropped by nearly six percentage points. Patients also responded positively, with 83% saying remote monitoring should continue as part of their diabetes care. Researchers hope to expand the program and study whether this approach can also benefit people newly diagnosed with type 1
diabetes.https://health.ucdavis.edu/news/headlines/remote-monitoring-program-improves-diabetes-management-for-youth-with-type-1-diabetes/2026/10
 
XX
A new editorial in Diabetes Care argues that pregnant women with type 1 diabetes are being left behind when it comes to automated insulin delivery technology. While AID systems have become the recommended treatment for people with T1D, most systems available in the U.S. aren't designed to meet the tighter glucose targets needed during pregnancy. The authors point out that pregnant women have routinely been excluded from clinical trials, leaving major gaps in research about how well these systems work during pregnancy. In fact, only four randomized trials worldwide have studied AID during pregnancy, involving just over 300 participants. The editorial calls on device manufacturers, researchers, and regulators to include pregnant women in clinical trials, develop pregnancy-specific technology, and collect more real-world data on existing systems. The authors say these changes are urgently needed to improve outcomes for both mothers and babies while reducing the burden of diabetes management during pregnancy.
T1d pregnancy and me study team, we did an episode on this.
XX
A sugar naturally found in red meat may help explain the connection between eating red meat and an increased risk of type 2 diabetes. Researchers in France followed nearly 90,000 adults and found that those who consumed the most of this sugar, called Neu5Gc, had a 63% higher risk of developing type 2 diabetes compared to those who consumed the least. Neu5Gc is found primarily in beef and lamb, and researchers believe it may trigger an immune response that leads to chronic inflammation. The association remained significant even after accounting for factors such as physical activity, diet, and body weight. However, when researchers adjusted for the total amount of red meat consumed, the association was no longer statistically significant, meaning they can't say whether the sugar itself is responsible for the increased risk. The findings were presented at the European Association for the Study of Diabetes annual meeting and are considered preliminary.
https://www.sciencedaily.com/releases/2026/10/261017230031.htm
XX
Breakthrough T1D, formerly JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, announces the conclusion of the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026).
 
From October 9-11, 2026, this landmark gathering of the global T1D community brought together world-renowned clinicians, researchers, scientists, healthcare professionals, industry leaders, people with lived experience, and community advocates in Philadelphia, Pennsylvania with the goal of improving lives and driving toward a world without T1D.
 
"Across the Congress, we looked at T1D from every angle: what we are learning about the disease, how that knowledge is shaping new treatments, and what people need from care today," said Dr Thomas Danne, Chief Medical Officer, International for Breakthrough T1D. "The most valuable discussions were the ones that connected those questions. That is how we make research more useful to the clinicians and communities it is meant to serve."
 
During CRC 2026, attendees explored the latest scientific and clinical advances during more than 80 sessions covering critical focus areas such as endocrinology, discovery science and immunotherapies, emerging technologies like AI and digital twins, islet cell and disease-modifying therapies, and access to care for the T1D community. Key moments from the two and half days of programming can be found in daily recaps below:
CRC 2026 Recap: Day 1
CRC 2026 Recap: Day 2
CRC 2026 Recap: Day 3 
We'll have more on this in an episode next week.
https://www.prnewswire.com/news-releases/breakthrough-t1d-concludes-inaugural-clinical--research-congress-highlighting-global-advances-in-type-1-diabetes-research-302906186.html
 
XX
Up next, Dexcom for type 2 and in athletes with T1D, technology news from omnipod and ascensia, and T1D takes the spotlight in the big leagues of baseball.. right after this.
XX
Ascensia Diabetes Care teams up with Sava Technologies to support the introduction and future commercialization of its wearable microsensor, currently under development. The technology is being designed to continuously monitor relevant biomarkers and molecules, starting with glucose, just beneath the skin.
Sava is planning for a pivotal clinical study for its CGM technology this year and aims to obtain CE approval and launch the microsensor within the next 18 to 24 months. Ascensia makes the CONTOUR® portfolio of blood glucose monitoring systems. They were partnered with Senseonics, the makers of the Eversense 365 implantable CGM but spun that business off last year
 
 
https://www.businesswire.com/news/home/20261008725757/en/Ascensia-Announces-Strategic-Partnership-with-Sava-for-Innovative-Microsensor-Technology
 
XX
Insulet Corporation announced the U.S. full market release of Omnipod Discover™, a web-based data platform designed for Omnipod 5 users, their caregivers, and healthcare providers (HCPs).
With Omnipod Discover, Omnipod 5 users get simple, personalized glucose and insulin delivery reports sent directly to their smartphone weekly, so they know where to focus their diabetes management efforts. Omnipod Discover also helps HCPs make confident clinical recommendations from a concise report by overlaying a licensed Ambulatory Glucose Profile (AGP) with key adjustable pump settings and bolus events.
 
In June, Insulet presented Real-World Glycemic Outcomes1 using the Omnipod Discover platform at the American Diabetes Association's Scientific Sessions in New Orleans, Louisiana. Use of Omnipod Discover was associated with improvements in time in range (TIR), with 32% of users seeing a clinically meaningful increase in TIR of 3% or more. These findings support the vital role that user engagement with Omnipod Discover can play in diabetes self-management.
https://investors.insulet.com/news/news-details/2026/Insulet-Announces-Omnipod-Discover-Now-Available-in-U-S-/default.aspx
XX
We talked about this study with Dexcom in our bonus episode last week, but it's worth revisiting now that the results have been published in the New England Journal of Medicine. The Dexcom-funded study found that people with type 2 diabetes who don't use insulin saw significant improvements in blood sugar management when using a continuous glucose monitor. After 26 weeks, participants using Dexcom's G7 lowered their average A1C from 8.8% to 7.2%, compared to a drop from 8.7% to 8% for those receiving routine care. CGM users also spent about five additional hours each day in their target glucose range. The findings come as Medicare considers expanding CGM coverage to people with diabetes who don't use insulin, potentially opening access to millions more Americans. A decision on that expansion is expected before the end of the year, although the timing remains uncertain.
https://www.medtechdive.com/news/nejm-study-supports-cgm-use-for-people-with-diabetes-who-dont-take-insulin/833124/
 
XX
New research from Dexcom suggests that more young adults with type 1 diabetes are staying involved in sports, and feelings of isolation and stigma are declining. The percentage who quit sports after diagnosis dropped from 24% in 2022 to 16% in 2026, while those reporting frequent loneliness fell from 28% to 15%. But challenges remain, with fear of low blood sugar and the complexity of managing diabetes during exercise among the biggest reasons people stop playing. The research also found that young adults who started using a CGM within a year of diagnosis reported fewer glucose management challenges and less fear of lows than those who started later. The findings come as Dexcom launches its fifth season of Dexcom U, featuring 27 college athletes with diabetes across 13 sports. The program aims to increase visibility and show young people with T1D what's possible.
XX
Dexcom has announced a new partnership with Team Novo Nordisk, the world's only professional cycling team made up entirely of athletes with diabetes. Dexcom will become the team's official continuous glucose monitoring partner, with plans to support research, education, and awareness about managing type 1 diabetes during demanding physical activity. Team co-founder Phil Southerland says seeing professional athletes using the same diabetes technology as kids at home can make a powerful difference. Cyclist David Lozano, who's been with the team since 2012, says CGM technology has transformed how he trains, allowing him to see where his glucose is heading rather than just where it's been. The partnership also aims to highlight the role of diabetes technology in helping people with T1D pursue their athletic goals.
XX
A powerful moment in Major League Baseball this week as Milwaukee Brewers outfielder Garrett Mitchell, who was diagnosed with type 1 diabetes at age 9, hit the game-winning home run that sent his team to the World Series. Mitchell has faced doubts throughout his career about whether he could stay healthy enough to handle a full baseball season, but this year he's played more games than in his previous four seasons combined. His father, Antony, says Garrett has always been motivated to prove people wrong, and that managing diabetes behind the scenes takes tremendous work. Mitchell uses an insulin pump and monitors his glucose throughout games, and he's also become a role model for young athletes with T1D. His dad summed up the emotional moment this way: "He has managed himself for many years, and here he is, an example to kids that anything is possible." And now, after helping the Brewers complete a remarkable comeback against the Dodgers, Mitchell is headed to the World Series.
https://www.mlb.com/news/garrett-mitchell-hits-go-ahead-homer-to-send-brewers-to-world-series

A new company brings together two technologies: lab-grown insulin-producing cells and an implantable pouch designed to help those cells survive and function inside the body. Sernova makes the pouch, Seraxis grows the cells – together they are BetaNova hopes that bringing these two technologies together could move us closer to a functional cure for type 1 diabetes.
So what does this merger really mean? What makes these cells different? And could this approach eventually work without immunosuppressive drugs and actually be available to millions of people with type 1?
I'm talking with the CEOs of the companies that are merging: Jonathan Rigby – who lives with type 1 -  and Will Rust about the science, the challenges, and why they believe this combination could be a game changer.
Our past episodes with Sernova here
This podcast is not intended as medical advice if you have those kinds of questions please contact your healthcare provider.
Check out all of our events like Moms' Night Out and Club 1921 here.

Announcing Community Commericals! Learn how to get your message on the show here.
Learn more about studies and research at Thrivable here
Please visit our Sponsors & Partners - they help make the show possible!
Omnipod - Simplify Life
All about Dexcom 
All about VIVI Cap to protect your insulin from extreme temperatures

The best way to keep up with Stacey and the show is by signing up for our weekly newsletter:
Sign up for our newsletter here

Here's where to find us:
Facebook (Group)
Facebook (Page)
Instagram
Check out Stacey's books!

Learn more about everything at our home page www.diabetes-connections.com